Chicago、ILにおける悪性黒色腫の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 他1件
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
被験者募集中第2相
- Northwestern University, Chicago
- University of Illinois, Chicago
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
被験者募集中第3相
- Northwestern University, Chicago
- Swedish Covenant Hospital, Chicago
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
被験者募集中第1/2相
- Northwestern University, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Lurie Children's Hospital-Chicago, Chicago
- Northwestern University, Chicago
- University of Illinois, Chicago
- 他1件
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
被験者募集中
- Northwestern University, Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
被験者募集中第1/2相
- Call for Information (Investigational Site 0024), Chicago
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
被験者募集中第1/2相
- University of Chicago, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
被験者募集中
- Advocate Illinois Masonic Medical Center, Chicago
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Nashville, TN33件の研究
- Pittsburgh, PA31件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- St. Louis, MO21件の研究
- Salt Lake City, UT21件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。